NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
Clinical Trials
161 trialsNCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT04362436 2026-01-14
ArTisaN
Imperial College London
Phase 2 Completed
NCT03455075 2025-10-30
Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
Premier Research
Phase 2 Completed
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT02820857 2025-09-03
BEVANEC
Hospices Civils de Lyon
Phase 2 Completed
NCT02973997 2025-08-29
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
Phase 2 Completed
NCT04300790 2025-07-29
METALLICA
MedSIR
Phase 2 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT00113360 2025-05-01
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03591731 2025-04-01
NIPINEC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03452111 2025-02-18
Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
Premier Research
Phase 2 Completed
NCT04438304 2025-02-12
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Phase 2 Completed
NCT02691078 2025-02-04
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT03095274 2025-01-09
DUNE
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT02724540 2025-01-06
Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT03837977 2024-12-30
NET02
The Christie NHS Foundation Trust
Phase 2 Completed
NCT03278379 2024-12-24
NET-002
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT03034200 2024-11-26
Phase 2 Study of ONC201 in Neuroendocrine Tumors
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02393690 2024-07-26
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT03870399 2024-05-06
HORMONET
AC Camargo Cancer Center
Phase 2 Completed
NCT03565536 2024-04-19
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Phase 2 Completed
NCT01466036 2024-03-05
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03012620 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT03008369 2024-02-20
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT00390325 2024-02-06
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02318784 2023-12-05
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01607879 2023-09-22
Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
Medical College of Wisconsin
Phase 2 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT01782443 2023-08-14
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04385992 2023-06-27
NeoLuPaNET
IRCCS San Raffaele
Phase 2 Completed
NCT01689727 2023-06-22
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Endocyte
Phase 2 Completed
NCT00193531 2023-04-11
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01237457 2023-03-20
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Excel Diagnostics and Nuclear Oncology Center
Phase 2 Completed
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03273712 2023-02-09
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
University of Iowa
Phase 2 Completed
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT03722511 2022-11-03
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs
University of Kentucky
Phase 2 Completed
NCT02651987 2022-10-03
CLARINET FORTE
Ipsen
Phase 2 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT03271281 2022-06-30
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
Rigshospitalet, Denmark
Phase 2 Completed
NCT03278275 2022-06-30
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
Rigshospitalet, Denmark
Phase 2 Completed